

Global Respiratory Drugs Pipeline Analysis Market 2018

<https://marketpublishers.com/r/G38C182A4EFEN.html>

Date: April 2018

Pages: 188

Price: US\$ 3,500.00 (Single User License)

ID: G38C182A4EFEN

Abstracts

Respiratory Drugs Pipeline Analysis

Overview: Pulmonary medicine is the branch of medical science that deals with diagnosis, prevention, and treatment of diseases affecting the respiratory system. Respiratory drugs finds its applications in Asthma, COPD, Cystic Fibrosis, Allergic Rhinitis and Others. Asthma is the major market share holder currently. The intensity of competition in the respiratory drug market is high with few players dominating the market. The high investments made in the development of respiratory drug delivery systems have favored the growth of the market. The entry of innovative and effective drugs in the market is expected to drive the future of the market.

Short-Acting Beta2-Agonists (SABA), Inhaled corticosteroids (ICS), anticholinergics, long-acting beta2-agonists (LABA), antihistamines, vasodilators, combination drugs, and others are the major respiratory drugs classes available in the market. Currently, primarily combination drugs drive the market, with top brands facing no real competition from generic alternatives. The emergence of inexpensive, state-of-the-art and effective drug delivery devices will provide stimulate the market growth.

Industry Trends

GSK's Advair for Asthma and COPD remains as the top selling drug in the market, even on declined revenue in 2017

Pharmaceutical companies in US are facing pricing pressure and launch of new respiratory drugs in the market are declining the sales of the blockbuster drugs in the market

Cipla Ltd., a leader in the Indian market, announced in May 2017, that it planned to reduce the investment on the biosimilars, to increase their focus on the respiratory drugs due to the high profitability

More than 30 companies pipeline for the respiratory drugs is analyzed in the study. GlaxoSmithKline plc has the highest number of pipeline molecules in various clinical trials phases.

Benefits: The report provides complete details about the usage and adoption rate of respiratory drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Contents

1 INDUSTRY OUTLOOK

- 1.1 Industry Overview
 - 1.1.1 Global Driver for Pharmaceutical Demand:
 - 1.1.2 Pharmaceutical spending region wise
 - 1.1.3 R&D pipeline in pharmaceutical industry
 - 1.1.4 Top pharma drugs by sales in 2017 (\$Million)
- 1.2 Industry Trends
- 1.3 Pest Analysis

2 REPORT OUTLINE

- 2.1 Report Scope
- 2.2 Report Summary
- 2.3 Research Methodology
- 2.4 Report Assumptions

3 MARKET SNAPSHOT

- 3.1 Market Definition – Infoholic Research
- 3.2 Segment Addressable Market
- 3.1 Trends of Respiratory Drugs Market

4 MOLECULE TYPE: ANALYSIS

- 4.1 Overview

5 APPLICATION: ANALYSIS

- 5.1 Overview
- 5.2 Asthma
 - 5.2.1 Key Takeaways
 - 5.2.2 Company Analysis
- 5.3 Chronic Obstructive Pulmonary Disease (COPD)
 - 5.3.1 Key Takeaways
 - 5.3.2 Company Analysis
- 5.4 Cystic Fibrosis

- 5.4.1 Key Takeaways
- 5.4.2 Company Analysis
- 5.5 Lung Cancer
 - 5.5.1 Key Takeaways
 - 5.5.2 Company Analysis
- 5.6 Nasal Polyps
 - 5.6.1 Key Takeaways
- 5.7 Idiopathic Pulmonary Fibrosis
 - 5.7.1 Key Takeaways
 - 5.7.2 Company Analysis
- 5.8 Others

6 COMPETITIVE LANDSCAPE

- 6.1.1 Company Analysis

7 VENDORS PROFILE

- 7.1 AbbVie Inc
 - 7.1.1 Overview
 - 7.1.2 Geographic Presence
 - 7.1.3 Business Focus
 - 7.1.4 SWOT Analysis
 - 7.1.5 Business Strategies
- 7.2 Amgen Inc
 - 7.2.1 Overview
 - 7.2.2 Geographic Presence
 - 7.2.3 Business Focus
 - 7.2.4 SWOT Analysis
 - 7.2.5 Business Strategies
- 7.3 Astra Zeneca PLC
 - 7.3.1 Overview
 - 7.3.2 Geographic Presence
 - 7.3.3 Business Focus
 - 7.3.4 SWOT Analysis
 - 7.3.5 Business Strategy
- 7.4 Bayer AG
 - 7.4.1 Overview
 - 7.4.2 Business Unit

- 7.4.3 Geographic Presence
- 7.4.4 Business Focus
- 7.4.5 SWOT Analysis
- 7.4.6 Business Strategy
- 7.5 Boehringer Ingelheim GmbH
 - 7.5.1 Overview
 - 7.5.2 Geographic Presence
 - 7.5.3 Business Focus
 - 7.5.4 SWOT Analysis
 - 7.5.5 Business Strategy
- 7.6 Bristol-Myers Squibb
 - 7.6.1 Overview
 - 7.6.2 Geographic Presence
 - 7.6.3 Business Focus
 - 7.6.4 SWOT Analysis
 - 7.6.5 Business Strategy
- 7.7 Celgene Corporation
 - 7.7.1 Overview
 - 7.7.2 Geographic Presence
 - 7.7.3 Business Focus
 - 7.7.4 SWOT Analysis
 - 7.7.5 Business Strategy
- 7.8 Dr .Reddy's Laboratories Limited
 - 7.8.1 Overview
 - 7.8.2 Business Unit
 - 7.8.3 Geographic Presence
 - 7.8.4 Business Focus
 - 7.8.5 SWOT Analysis
 - 7.8.6 Business Strategy
- 7.9 Eli Lilly & Company Ltd
 - 7.9.1 Overview
 - 7.9.2 Business Focus
 - 7.9.3 SWOT Analysis
 - 7.9.4 Business Strategies
- 7.10 F.Hoffmann-La Roche Ltd
 - 7.10.1 Overview
 - 7.10.2 Business Unit
 - 7.10.3 Geographic Presence
 - 7.10.4 Business Focus

- 7.10.5 SWOT Analysis
- 7.10.6 Business Strategy
- 7.11 GlaxoSmithKline plc
 - 7.11.1 Overview
 - 7.11.2 Geographic Presence
 - 7.11.3 Business Focus
 - 7.11.4 SWOT Analysis
 - 7.11.5 Business Strategy
- 7.12 Johnson & Johnson
 - 7.12.1 Overview
 - 7.12.2 Business Units
 - 7.12.3 Geographic Revenue
 - 7.12.4 Business Focus
 - 7.12.5 SWOT Analysis
 - 7.12.6 Business Strategies
- 7.13 Merck & Co., Inc.
 - 7.13.1 Overview
 - 7.13.2 Business units
 - 7.13.3 Geographic Revenue
 - 7.13.4 Business focus
 - 7.13.5 SWOT analysis
 - 7.13.6 Business strategies
- 7.14 Mylan N.V.
 - 7.14.1 Overview
 - 7.14.2 Geographic Presence
 - 7.14.3 Business Focus
 - 7.14.4 SWOT Analysis
 - 7.14.5 Business Strategy
- 7.15 Novartis AG
 - 7.15.1 Overview
 - 7.15.2 Business Unit
 - 7.15.3 Geographic Presence
 - 7.15.4 Business Focus
 - 7.15.5 SWOT Analysis
 - 7.15.6 Business Strategy
- 7.16 Pfizer, Inc.,
 - 7.16.1 Overview
 - 7.16.2 Business Units
 - 7.16.3 Geographic Presence

- 7.16.4 Business Focus
- 7.16.5 SWOT Analysis
- 7.16.6 Business Strategies
- 7.17 Sanofi
 - 7.17.1 Overview
 - 7.17.2 Geographic Presence
 - 7.17.3 Business Focus
 - 7.17.4 SWOT Analysis
 - 7.17.5 Business Strategy
- 7.18 Teva Pharmaceutical Industries Ltd
 - 7.18.1 Overview
 - 7.18.2 Business Unit
 - 7.18.3 Geographic Presence
 - 7.18.4 Business focus
 - 7.18.5 SWOT analysis
 - 7.18.6 Business Strategy
- 7.19 Vertex Pharmaceuticals Inc
 - 7.19.1 Overview
 - 7.19.2 Geographic Presence
 - 7.19.3 Business Focus
 - 7.19.4 SWOT Analysis
 - 7.19.5 Business Strategy

8 COMPANIES TO WATCH FOR

- 8.1 FibroGen, Inc
 - 8.1.1 Overview
 - 8.1.2 Highlights
- 8.2 Gilead Sciences Inc
 - 8.2.1 Overview
 - 8.2.2 Highlights:
- 8.3 Glenmark Pharmaceutical Ltd
 - 8.3.1 Overview
- 8.4 Zia Labs
 - 8.4.1 Overview
 - 8.4.2 Zia Lab: Highlights
- 8.5 Vectura Group Plc
 - 8.5.1 Overview
 - 8.5.2 Vectura Group Plc: Highlights

- 8.6 Sosei Group Corporation
 - 8.6.1 Overview
- 8.7 Almirall S.A
 - 8.7.1 Overview
- 8.8 Biogen Inc
 - 8.8.1 Overview
- 8.9 CHIESI Farmaceutici SpA
 - 8.9.1 Overview
 - 8.9.2 CHIESI Farmaceutici SpA: Highlights
- 8.10 Takeda Pharmaceutical Co, Ltd
 - 8.10.1 Overview
 - 8.10.2 Highlights
- 8.11 Shionogi & Co., Ltd
 - 8.11.1 Overview
 - 8.11.2 Shionogi & Co., Ltd: Highlights
- 8.12 Sun Pharmaceuticals
 - 8.12.1 Overview
 - 8.12.2 Highlights
- 8.13 United Therapeutics Corp
 - 8.13.1 Overview
 - 8.13.2 Highlights
- 8.14 ProMetic Life Sciences Inc
 - 8.14.1 Overview
 - 8.14.2 ProMetic Life Sciences Inc.: Highlights
- 8.15 Daiichi Sankyo, Inc
 - 8.15.1 Overview
 - 8.15.2 Overview
- 8.16 Aurobindo Pharma Ltd
 - 8.16.1 Overview
 - 8.16.2 Aurobindo Pharma Ltd: Highlights
- 8.17 Eisai Co., Ltd
 - 8.17.1 Overview
 - 8.17.2 Eisai Co., Ltd: Highlights
- 8.18 Shire Plc
 - 8.18.1 Overview
 - 8.18.2 Shire Plc: Highlights
- 8.19 GNI Group Ltd
 - 8.19.1 Overview
- 8.20 MediciNova, Inc

8.20.1 Overview

8.21 Ono Pharmaceutical Co., Ltd

8.21.1 Overview

8.22 Promedior, Inc

8.22.1 Overview

8.23 Sumitomo Dainippon Pharma Co., Ltd

8.23.1 Overview

8.23.2 Sumitomo Dainippon Pharma Co., Ltd: Highlights

9 ANNEXURE

Abbreviations

List Of Tables

LIST OF TABLES

Table 1	MOLECULES IN PIPELINE FOR ASTHMA
Table 2	MOLECULES IN PIPELINE FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER
Table 3	MOLECULES IN PIPELINE FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER
Table 4	MOLECULES IN PIPELINE FOR LUNG CANCER
Table 5	MOLECULES IN PIPELINE FOR IDOPATHIC PULMONARY FIBROSIS
Table 6	MOLECULES IN PIPELINE FOR IDOPATHIC PULMONARY FIBROSIS
Table 7	ABBVIE INC.: OFFERINGS
Table 8	ABBVIE INC: RECENT DEVELOPMENTS
Table 9	AMGEN INC.: OFFERINGS
Table 10	AMGEN INC.: RECENT DEVELOPMENTS
Table 11	ASTRA ZENCA PLC: OFFERINGS
Table 12	ASTRA ZENCA PLC: RECENT DEVELOPMENTS
Table 13	BAYER AG: OFFERINGS
Table 14	BAYER AG: RECENT DEVELOPMENTS
Table 15	BOEHRINGER INGELHEIM GMBH: OFFERINGS
Table 16	BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS
Table 17	BRISTOL-MYERS SQUIBB: OFFERINGS
Table 18	BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT
Table 19	CELGENE CORPORATION: OFFERINGS
Table 20	CELGENE CORPORATION: RECENT DEVELOPMENTS
Table 21	DR .REDDY'S LABORATORIES LIMITED: PRODUCT OFFERINGS
Table 22	DR .REDDY'S LABORATORIES LIMITED: RECENT DEVELOPMENTS
Table 23	ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS
Table 24	ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS
Table 25	F .HOFFMANN-LA ROCHE LTD.: OFFERINGS
Table 26	F .HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
Table 27	GLAXOSMITHKLINE PLC: OFFERINGS
Table 28	GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
Table 29	JOHNSON & JOHNSON: PRODUCT OFFERINGS
Table 30	JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 31	MERCK & CO: PRODUCT OFFERINGS
Table 32	MERCK & CO: RECENT DEVELOPMENTS
Table 33	MYLAN N.V.: OFFERINGS

Table 34 MYLAN N.V.: RECENT DEVELOPMENT

Table 35 NOVARTIS AG: OFFERINGS

Table 36 NOVARTIS AG: RECENT DEVELOPMENTS

Table 37 PFIZER, INC.: OFFERINGS

Table 38 PFIZER, INC.: RECENT DEVELOPMENTS

Table 39 SANOFI: OFFERINGS

Table 40 SANOFI: RECENT DEVELOPMENTS

Table 41 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS

Table 42 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS

Table 43 VERTEX PHARMACEUTICALS INC.: OFFERINGS

Table 44 VERTEX PHARMACEUTICALS INC.: RECENT DEVELOPMENTS

Table 45 FIBROGEN, INC: OVERVIEW

Table 46 FIBROGEN INC: RECENT DEVELOPMENTS

Table 47 GILEAD SCIENCES INC.: OVERVIEW

Table 48 GILEAD SCIENCE INC: RECENT DEVELOPMENTS

Table 49 GLENMARK PHARMACEUTICAL LTD: OVERVIEW

Table 50 GLENMARK PHARMACEUTICAL LTD: RECENT DEVELOPMENTS

Table 51 ZIA LAB: OVERVIEW

Table 52 ZIA LAB: RECENT DEVELOPMENTS

Table 53 VECTURA GROUP PLC: OVERVIEW

Table 54 VECTURA GROUP AG: RECENT DEVELOPMENTS

Table 55 SOSEI GROUP CORPORATION: OVERVIEW

Table 56 SOSEI GROUP CORPORATION: RECENT DEVELOPMENTS

Table 57 ALMIRALL S.A: OVERVIEW

Table 58 ALMIRALL S.A.: RECENT DEVELOPMENTS

Table 59 BIOGEN INC: OVERVIEW

Table 60 BIOGEN INC: RECENT DEVELOPMENTS

Table 61 CHIESI FARMACEUTICI SPA: OVERVIEW

Table 62 CHIESI FARMACEUTICI SPA: RECENT DEVELOPMENTS

Table 63 TAKEDA PHARMACEUTICAL CO, LTD.: OVERVIEW

Table 64 TAKEDA PHARMACEUTICAL CO, LTD: RECENT DEVELOPMENTS

Table 65 SHIONOGI & CO., LTD: OVERVIEW

Table 66 SHIONOGI & CO., LTD: RECENT DEVELOPMENTS

Table 67 SUN PHARMACEUTICALS: OVERVIEW

Table 68 ZIA LAB: RECENT DEVELOPMENTS

Table 69 UNITED THERAPEUTICS CORP.: OVERVIEW

Table 70 PROMETIC LIFE SCIENCES INC.: OVERVIEW

Table 71 PROMETIC LIFE SCIENCES INC.: RECENT DEVELOPMENTS

Table 72 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS

Table 73 AUROBINDO PHARMA LTD: OVERVIEW

Table 74 AUROBINDO PHARMA LTD: RECENT DEVELOPMENTS

Table 75 EISAI CO., LTD: OVERVIEW

Table 76 EISAI CO., LTD: RECENT DEVELOPMENTS

Table 77 SHIRE PLC: OVERVIEW

Table 78 SHIRE PLC: RECENT DEVELOPMENTS

Table 79 GNI GROUP LTD: OVERVIEW

Table 80 GNI GROUP LTD: RECENT DEVELOPMENTS

Table 81 MEDICINOVA INC: OVERVIEW

Table 82 MEDICINOVA INC: RECENT DEVELOPMENTS

Table 83 ONO PHARMACEUTICAL CO., LTD: OVERVIEW

Table 84 ONO PHARMACEUTICAL CO., LTD: RECENT DEVELOPMENTS

Table 85 PROMEDIOR, INC: OVERVIEW

Table 86 PROMEDIOR INC: RECENT DEVELOPMENTS

Table 87 SUMITOMO DAINIPPON PHARMA CO., LTD: OVERVIEW

Table 88 SUMITOMO DAINIPPON PHARMA CO., LTD: RECENT DEVELOPMENTS

List Of Charts

LIST OF CHARTS

Chart 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016)

Chart 2 PHARMACEUTICAL MOLECULES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS)

Chart 3 R&D INVESTMENT BY TOP 10 COMPANIES (\$BN)

Chart 4 PHARMACEUTICAL DRUGS BY SALES, 2017

Chart 5 PEST ANALYSIS OF RESPIRATORY DRUGS MARKET

Chart 6 RESEARCH METHODOLOGY OF RESPIRATORY DRUGS PIPELINE

Chart 7 NUMBER OF LARGE MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS

Chart 8 NUMBER OF SMALL MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS

Chart 9 RESPIRATORY PRODUCT PIPELINE BASED ON THE MOLECULE TYPE

Chart 1 RESPIRATORY DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 VS 2024 (%)

Chart 2 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR ASTHMA

Chart 3 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER

Chart 4 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER

Chart 5 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR LUNG CANCER

Chart 6 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR LUNG CANCER

Chart 7 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR IDOPATHIC PULMONARY FIBROSIS

Chart 8 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR OTHER RESPIRATORY DISEASES

Chart 9 ABBVIEE INC: OVERVIEW SNAPSHOT

Chart 10 ABBVIEE INC.: GEOGRAPHIC PRESENCE

Chart 11 ABBVIE INC.: SWOT ANALYSIS

Chart 12 AMGEN INC.: OVERVIEW SNAPSHOT

Chart 13 AMGEN INC.: GEOGRAPHIC PRESENCE

Chart 14 AMGEN: SWOT ANALYSIS

Chart 15 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT

- Chart 16 ASTRA ZENCA PLC: BUSINESS UNITS
- Chart 17 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE
- Chart 18 ASTRA ZENCA PLC: SWOT ANALYSIS
- Chart 19 BAYER AG: OVERVIEW SNAPSHOT
- Chart 20 BAYER AG: BUSINESS UNITS
- Chart 21 BAYER GA: GEOGRAPHICAL PRESENCE
- Chart 22 BAYER AG: SWOT ANALYSIS
- Chart 23 BOEHRINGER INGELHEIM GMBH: OVERVIEW SNAPSHOT
- Chart 24 BOEHRINGER INGELHEIM GMBH: BUSINESS UNITS
- Chart 25 BOEHRINGER INGELHEIM GMBH: GEOGRAPHIC PRESENCE
- Chart 26 BOEHRINGER INGELHEIM GMBH: SWOT ANALYSIS
- Chart 27 BRISTOL-MYERS SQUIBB.: OVERVIEW SNAPSHOT
- Chart 28 BRISTOL-MYERS SQUIBB.: BUSINESS SEGMENTS
- Chart 29 BRISTOL-MYERS SQUIBB.: GEOGRAPHIC PRESENCE
- Chart 30 BRISTOL-MYERS SQUIBB.: SWOT ANALYSIS
- Chart 31 CELGENE CORPORATION: OVERVIEW SNAPSHOT
- Chart 32 CELGENE CORPORATION: GEOGRAPHIC PRESENCE
- Chart 33 CELGENE CORPORATION: SWOT ANALYSIS
- Chart 34 DR .REDDY'S LABORATORY LIMITED: OVERVIEW SNAPSHOT
- Chart 35 DR .REDDY'S LABORATORY LIMITED: BUSINESS UNITS
- Chart 36 DR .REDDY'S LABORATORY LIMITED: GEOGRAPHICAL PRESENCE
- Chart 37 DR .REDDY'S LABORATORY LIMITED: SWOT ANALYSIS
- Chart 38 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT
- Chart 39 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT
- Chart 40 ELI LILLY & COMPANY LTD.: GEOGRAPHIC REVENUE
- Chart 41 ELI LILLY & COMPANY LTD.: SWOT ANALYSIS
- Chart 42 F .HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT
- Chart 43 F .HOFFMANN.LA ROCHE LTD.: BUSINESS UNITS
- Chart 44 F .HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE
- Chart 45 F .HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
- Chart 46 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT
- Chart 47 GLAXOSMITHKLINE PLC: BUSINESS UNITS
- Chart 48 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE
- Chart 49 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
- Chart 50 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
- Chart 51 JOHNSON & JOHNSON: BUSINESS UNITS
- Chart 52 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
- Chart 53 JOHNSON & JOHNSON: SWOT ANALYSIS
- Chart 54 MERCK & CO: OVERVIEW SNAPSHOT

- Chart 55 MERCK & CO: BUSINESS UNITS
- Chart 56 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
- Chart 57 MERCK & CO: SWOT ANALYSIS
- Chart 58 MYLAN N.V .OVERVIEW SNAPSHOT
- Chart 59 MYLAN N.V.: BUSINESS SEGMENTS
- Chart 60 MYLAN N.V.: GEOGRAPHIC PRESENCE
- Chart 61 MYLAN N.V.: SWOT ANALYSIS
- Chart 62 NOVARTIS AG: OVERVIEW SNAPSHOT
- Chart 63 NOVARTIS AG: BUSINESS UNITS
- Chart 64 NOVARTIS AG: GEOGRAPHICAL PRESENCE
- Chart 65 NOVARTIS AG: SWOT ANALYSIS
- Chart 66 PFIZER, INC.: OVERVIEW SNAPSHOT
- Chart 67 PFIZER INC.: BUSINESS UNITS
- Chart 68 PFIZER INC.: GEOGRAPHIC PRESENCE
- Chart 69 PFIZER INC: SWOT ANALYSIS
- Chart 70 SANOFI SA: OVERVIEW SNAPSHOT
- Chart 71 SANOFI SA: SEGMENTATION
- Chart 72 SANOFI SA: GEOGRAPHIC REVENUE
- Chart 73 SANOFI SA: SWOT ANALYSIS
- Chart 74 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT
- Chart 75 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS
- Chart 76 TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL PRESENCE
- Chart 77 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
- Chart 78 VERTEX PHARMACEUTICALS INC.: OVERVIEW SNAPSHOT
- Chart 79 VERTEX PHARMACEUTICALS INC.: GEOGRAPHICAL PRESENCE
- Chart 80 VERTEX PHARMACEUTICALS INC.: SWOT ANALYSIS

I would like to order

Product name: Global Respiratory Drugs Pipeline Analysis Market 2018

Product link: <https://marketpublishers.com/r/G38C182A4EFEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G38C182A4EFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970